Offer Price
Offer Size
3-Year Outlook
Volatility
1st Day Turnover
$7.50
2,700,000
Positive
High
0.7%
Offering Team
Deal Managers
- Joseph Stone Capital
Lawyers
- Sichenzia Ross Ference Carmel LLP
Auditors
- Marcum LLP
Pre-IPO Investors
Investors
- Google Ventures
- Intel Ventures
- Patricoff Ventures
- Kleiner Perkins
Pre-IPO Holdings(%)
- 30
- 20
- 05
- 18
Deal Highlights
We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since our inception in 2002, we have built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and develop More
Deal Tracker
Investors
Filing
07 Mar, 2024Offer
17 Jun, 2025Look Ahead
Lock Up Expiry
17 Dec, 2025Earning
Nov 1, 2018IPO Terms
| Offer Price | $7.50 |
| Offer Size | 2M |